Shire, Shionogi in Strategic ADHD Pact

Shire has entered into an agreement with Shionogi to co-develop and co-commercialize Shire’s Attention Deficit Hyperactivity Disorder (ADHD) medicines in Japan. Shionogi will pay a one-time fee and share costs in exchange for rights to jointly develop and commercialize the products for the Japanese market. Specific terms were not disclosed.

“Providing support for ADHD patients, their families and the medical community who treat these patients is at the heart of our approach at Shire, and this agreement with Shionogi underscores our commitment to helping patients diagnosed with ADHD,” said Mike Yasick, senior vice president of Shire’s ADHD business. “We look forward to working with the Shionogi team on efforts to enhance awareness in Japan about the impact undiagnosed and untreated ADHD can have on our societies, and the value that new treatment options can deliver for ADHD patients.”

Gian Piero Reverberi, senior vice president of Shire’s International Specialty Pharma business, added, “Our agreement with Shionogi further demonstrates Shire’s commitment to enabling greater patient access to Shire’s growing portfolio of specialist therapeutics around the globe and specifically to the Japanese market.”